2,350 Shares in Lantheus Holdings, Inc. (NASDAQ:LNTH) Bought by Everence Capital Management Inc.

Everence Capital Management Inc. purchased a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 2,350 shares of the medical equipment provider’s stock, valued at approximately $210,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Farallon Capital Management LLC raised its position in shares of Lantheus by 53.7% in the 2nd quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider’s stock valued at $182,999,000 after purchasing an additional 796,000 shares during the last quarter. Groupama Asset Managment acquired a new position in Lantheus during the 3rd quarter valued at approximately $439,000. Point72 Asset Management L.P. purchased a new position in shares of Lantheus in the second quarter worth $26,794,000. Janus Henderson Group PLC lifted its stake in shares of Lantheus by 7.7% during the third quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider’s stock worth $393,844,000 after buying an additional 257,022 shares during the period. Finally, Massachusetts Financial Services Co. MA purchased a new stake in shares of Lantheus during the third quarter valued at $25,955,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently issued reports on LNTH. Truist Financial restated a “buy” rating and issued a $120.00 target price (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. The Goldman Sachs Group began coverage on shares of Lantheus in a report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price target on the stock. Finally, JMP Securities decreased their price objective on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a research note on Thursday, November 7th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $131.86.

Lantheus Trading Down 3.0 %

Lantheus stock opened at $94.00 on Thursday. The firm has a market cap of $6.54 billion, a PE ratio of 15.64 and a beta of 0.46. The stock’s 50 day simple moving average is $91.26 and its two-hundred day simple moving average is $99.37. Lantheus Holdings, Inc. has a 12 month low of $50.20 and a 12 month high of $126.89.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.